The company bioProtonics, which specializes in advanced medical imaging platforms and proprietary Magnetic Resonance Histology (MRH) technology, has named A. Burton Tripathi as its chief executive officer.

The Santa Barbara-based company has also completed an initial closing of bridge financing, positioning it for accelerated clinical development.

Tripathi brings executive experience, including two exits in MedTech, spanning strategic innovation, product management, and the commercialization of disruptive technologies, according to bioProtonics.

“In this new role, his fourth as CEO, he will guide bioProtonics through its next critical phase of growth as the company prepares to validate its proprietary imaging solutions in the clinical setting,” the company said.

“I am thrilled to lead bioProtonics at such a pivotal moment in our trajectory,” said Tripathi. “We have an incredible opportunity to transform medical imaging and provide unprecedented insights for patient care.

“This bridge funding, combined with continued investor interest, is a strong vote of confidence which provides us with the momentum we need. Our immediate focus is on executing our upcoming clinical initiatives. We look forward to these clinical results, which will build the essential foundation for our Series A financing and our broader commercial strategy.”

The newly secured bridge capital will directly fund the company’s immediate clinical and operational milestones, the company said.

“BioProtonics anticipates that the forthcoming clinical data will powerfully demonstrate the efficacy and market potential of its patented imaging algorithms, paving the way for a robust Series A round to scale operations and drive future market entry,” company officials said.

For more, visit https://www.bioprotonics.com/.